DDInter948 DDInter463
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
Dacarbazine {u} (Compound) binds {v} (Gene) POLA2
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
Dacarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Dacarbazine {u} (Compound) downregulates {v} (Gene) HMGCS1
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Dacarbazine {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Dacarbazine (Compound) treats skin cancer (Disease)
Dacarbazine (Compound) binds POLA2 (Gene)
Dacarbazine (Compound) upregulates CADM1 (Gene)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Dacarbazine (Compound) downregulates HMGCS1 (Gene)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin